Loading clinical trials...
Loading clinical trials...
Randomized Multicenter Open-Label, Pilot Trial to Evaluate the Efficacy and Safety of Switching HIV-1 Stable Infected Patients Under HAART to a New Once Daily Triple Therapy Combination Including EFV+3TC+TDF Versus a Dual QD Therapy Containing EFV+TDF
Conditions
Interventions
EFV+TDF
EFV+3TC+TDF
Locations
1
France
France and French West Indies
Paris, France
Start Date
March 1, 2003
Primary Completion Date
June 1, 2005
Completion Date
September 1, 2005
Last Updated
June 30, 2008
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions